FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesThe Use of Direct-to-Patient Methods in Decentralized Clinical Trials in Israel
Topic: Direct-to-Patient
White Paper
Free
Reimagining Clinical Trial Surplus: Harnessing Donations to Close the Global Healthcare Gap
Topics: Supply Chain, Sustainability
White Paper
Free
Lessons Learned: Conducting COVID Clinical Trials and Building a Clinical Supplies Team During the Peak of the Pandemic
Topics: Conference, COVID-19
Executive Summary
Members
